Carr Financial Group Corp Grows Stock Position in Novo Nordisk A/S (NYSE:NVO)

Carr Financial Group Corp increased its holdings in Novo Nordisk A/S (NYSE:NVO) by 14.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,393 shares of the company’s stock after buying an additional 293 shares during the quarter. Carr Financial Group Corp’s holdings in Novo Nordisk A/S were worth $206,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Xponance Inc. increased its stake in shares of Novo Nordisk A/S by 27.6% in the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after purchasing an additional 576 shares in the last quarter. AQR Capital Management LLC grew its holdings in Novo Nordisk A/S by 110.5% during the second quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after purchasing an additional 9,012 shares during the period. Daymark Wealth Partners LLC increased its position in Novo Nordisk A/S by 15.9% in the second quarter. Daymark Wealth Partners LLC now owns 6,290 shares of the company’s stock worth $898,000 after buying an additional 864 shares in the last quarter. Maverick Capital Ltd. raised its stake in shares of Novo Nordisk A/S by 272.9% in the second quarter. Maverick Capital Ltd. now owns 7,849 shares of the company’s stock worth $1,120,000 after buying an additional 5,744 shares during the period. Finally, Matrix Private Capital Group LLC lifted its position in shares of Novo Nordisk A/S by 7.9% during the 2nd quarter. Matrix Private Capital Group LLC now owns 1,757 shares of the company’s stock valued at $251,000 after buying an additional 129 shares in the last quarter. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Price Performance

Shares of Novo Nordisk A/S stock opened at $87.94 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The company has a market capitalization of $394.65 billion, a price-to-earnings ratio of 28.46, a PEG ratio of 0.90 and a beta of 0.45. Novo Nordisk A/S has a 52 week low of $78.17 and a 52 week high of $148.15. The stock’s 50-day simple moving average is $95.62 and its 200-day simple moving average is $115.55.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on NVO shares. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a report on Monday, December 23rd. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $145.25.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.